President and Chief Executive Officer
Stephen S. Tang, Ph.D. became President and CEO of OraSure on April 1, 2018. Prior to becoming President and CEO, Dr. Tang joined the OraSure Board in April of 2011 and was the Company’s Chairman of the Board since November 2017. Prior to joining OraSure, Dr. Tang served as President and Chief Executive Officer of The University City Science Center, an urban research park and business incubator owned by over thirty leading universities, medical schools and health networks in the greater Philadelphia, Pennsylvania area. Prior to that, Dr. Tang held senior management and business development positions with several firms in the life sciences industry, including Olympus America, Inc., Millennium Cell Inc. and A.T. Kearney Inc. Dr. Tang holds a B.S. degree in Chemistry from The College of William and Mary, an M.S. degree and Ph.D. in Chemical Engineering from Lehigh University and an M.B.A. from The Wharton School of Business at the University of Pennsylvania.
Chief Financial Officer
Roberto Cuca joined OraSure in May 2018, initially serving as Senior Advisor to the Company until his appointment as the Company’s Chief Financial Officer in June 2018. Prior to joining OraSure, Mr. Cuca served as Senior Vice President and Chief Financial Officer of Trevena, Inc., a clinical stage biopharmaceutical company, where he led the finance and investor relations functions and worked with senior management to establish and execute overall corporate strategy. Prior to his tenure with Trevana, Mr. Cuca held various leadership positions in the finance organization of Endo Health Solutions Inc., a pharmaceutical company, including Treasurer and Senior Vice President, Finance, where he was responsible for capital raises and cash management, mergers, acquisitions and licensing transactions, tax planning and compliance, and risk management. Before he joined Endo, Mr. Cuca served as the Director, Corporate and Business Development at moksha8 Pharmaceuticals, Inc., an emerging markets-focused pharmaceutical company, and as an equity analyst covering U.S. pharmaceutical companies at J.P. Morgan Chase & Co. Mr. Cuca received an M.B.A. from the Wharton School of the University of Pennsylvania, a Juris Doctor from Cornell Law School, and an A.B. from Princeton University. Mr. Cuca is also a CFA Charterholder.
Executive Vice President, Business Unit Leader, Infectious Disease
Tony Zezzo has been the Executive Vice President, Business Unit Leader, Infectious Disease since January 2017, and prior to that served as Executive Vice President, Marketing and Sales since January 2011. Prior to joining OraSure, Mr. Zezzo was Vice President, North America Sales and Marketing at the Ortho-Clinical Diagnostics division of Johnson & Johnson. Mr. Zezzo also held a series of sales and marketing positions of increasing responsibility within Johnson & Johnson. Mr. Zezzo received a B.A. degree in Political Science from Grove City College.
Senior Vice President, General Counsel and Secretary
Jack E. Jerrett has been the Company’s Senior Vice President and General Counsel since February 2003 and served as the Vice President and General Counsel since November 2000. He has also served as the Company’s Secretary since February 2001. Prior to joining the Company, Mr. Jerrett worked as an Associate at Morgan, Lewis & Bockius and held positions of increasing legal responsibilities with companies in the transportation and energy industries. Mr. Jerrett received a B.S. degree in Accounting from Villanova University and a Juris Doctor from the Villanova University School of Law. He is a member of the Pennsylvania Bar and the American and Pennsylvania Bar Associations.
Senior Vice President, Operations
Nancy McLane has been the Senior Vice President, Operations since December 2009. Prior to joining OraSure, Ms. McLane was Senior Vice President of Operations at Lifesync Corporation where she had responsibility for operations, quality assurance, regulatory affairs, and global supply chain and customer service for a medical device start-up that specializes in wireless electrocardiogram systems. Prior to that, she served as Executive Director of Operations at Cordis Corporation, a Johnson & Johnson company, where she had roles in operations management and new product development support. Prior to her work at Johnson & Johnson, Ms. McLane spent thirteen years at C.R. Bard, a multi-national producer and distributor of medical devices, where she held roles as Plant Manager at facilities in the U.S. and Mexico. Ms. McLane received a B.S. degree in Civil Engineering from Worcester Polytechnic Institute, an M.S. degree in Environmental Engineering from Northeastern University and an M.B.A. from Bentley College.
Senior Vice President, Business Development
David Rappaport has been the Senior Vice President, Business Development since April 2018. Prior to joining OraSure, Mr. Rappaport served as the Senior Vice President, Healthcare Investment Banking at Raymond James & Associates where he provided investment banking services in the Life Sciences practice group. Prior to his tenure at Raymond James, Mr. Rappaport served as a healthcare investment banker with Inverness Advisors, LLC, Thomas Weisel Partners, and SG Cowen. Mr. Rappaport received a Bachelors of Business Administration in Finance and Economics from the University of Wisconsin and an MBA from Emory University.
Senior Vice President, Research and Development and Chief Science Officer
Michael Reed, Ph.D. has been the Senior Vice President of Research and Development and Chief Science Officer since April 2016. Prior to joining the Company, Dr. Reed spent eight years at Beckman Coulter, a global diagnostics and life sciences company within the Danaher Corporation, serving in a variety of leadership positions, including Director of Global Assay and Applications Development for the Beckman Coulter Life Science business and Director of Scientific Affairs for the Cellular Analysis Business Group. Under his leadership, Beckman Coulter launched and commercialized over 300 products globally across multiple disciplines. Prior to his work at Beckman Coulter, Dr. Reed served as Director of Product Development with Osmetech Molecular Diagnostics where he led the effort to develop two U.S. FDA 510(K) cleared IVD systems for cystic fibrosis genotyping and a pharmacogenetics test to guide warfarin dosing. Dr. Reed received a Ph.D. in Biochemistry from the University of Adelaide (Australia) and a BSc. degree in Biochemistry from The Australian National University (Canberra, Australia). He also conducted post-doctoral research at the Beckman Research Institute at the City of Hope in Duarte, California.
Executive Vice President Innovation & Vice Chair DNA Genotek
Brian Smith was named Executive Vice President, Innovation & Vice Chair DNA Genotek in January 2019. Brian has over 25 years domestic and international marketing and business development experience. He has applied his knowledge and expertise commercializing innovative technology in early stage markets to numerous early stage and small cap companies. Prior to joining DNA Genotek, he was Director of Sales and Marketing for Telephonetics VIP plc, a UK speech recognition company, after having orchestrated the sale of Voice Integrated Products to Telephonetics plc. Previous positions include Vice President of Marketing at Cloakware Corporation (Ottawa), President of Ponte Communications (California), and executive positions at Entrust Technologies in both North America and Europe. Brian has a Bachelor of Commerce from McGill University with a major in Management Information Systems.
Executive Vice President, Business Unit Leader, Molecular Solutions
Kathleen Weber was named Executive Vice President, Business Unit Leader for Molecular Solutions in January 2019. In this role, she has oversight for the commercial, operational and financial performance of the business unit, which is also known as DNA Genotek. Kathy joined OraSure in 2012 as the Senior Vice President and General Manager, Consumer Products. Her role evolved from 2012 to 2018 to also include at various points in time managing the Emerging Disease Portfolio and leading the development of OraSure’s corporate strategy. Prior to joining OraSure, Ms. Weber held several senior commercial leadership positions at Pfizer, Johnson and Johnson and Schering–Plough. Ms. Weber began her career in the financial services industry and held various positions in U.S. and global marketing and operations at Chase Manhattan Bank, now part of JP Morgan Chase. Ms. Weber received a B.S. degree in business administration from Georgetown University and earned an M.B.A. from New York University’s Stern School of Business.